Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical and Immunological Study of Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata: A Randomized Controlled Clinical Trial
Brief Summary: Alopecia areata (AA) is a disease of the hair follicles with multifactorial etiology and a strong component of autoimmune origin. It is characterized by non-scarring hair loss on the scalp or any hair-bearing surface.

Various therapeutic agents have been described for the treatment of AA, but none are curative or preventive. The aim of AA treatment is to suppress the activity of the disease. Phototherapy in the form of topical psoralen and ultraviolet A (PUVA) has been a well documented therapy for AA since 1978.

A more recent technique of topical PUVA, namely phototoxic PUVA, has been adopted in two previous studies. Sessions were carried out once every 3 months, and a higher efficacy with more encouraging response rates in comparison to the conventional PUVA therapy has been documented. This assumed upper hand over the conventional PUVA might be due to increasing the amount of UV reaching the hair follicle cells and the surrounding inflammatory cells. Also it has been suggested that it might play a role as a powerful initiating agent of suppression through direct action at the DNA level. However, still the exact effect of this treatment has not been fully clarified.


Options:
A: Arm Label: Phototherapeutic; Type: EXPERIMENTAL; Interventions: Radiation: ultraviolet A (UVA) | Arm Label: Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Triamcinolone Acetonide | Intervention Type: RADIATION; Name: ultraviolet A (UVA); Assigned to Arm(s): Phototherapeutic | Intervention Type: DRUG; Name: Triamcinolone Acetonide; Assigned to Arm(s): Conventional therapy
B: Arm Label: Hydrocortisone 1%; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone 1% | Arm Label: Clobetasol Propionate 0.05%; Type: EXPERIMENTAL; Interventions: Drug: Clobetasol Propionate 0.05% | Intervention Type: DRUG; Name: Hydrocortisone 1%; Assigned to Arm(s): Hydrocortisone 1% | Intervention Type: DRUG; Name: Clobetasol Propionate 0.05%; Assigned to Arm(s): Clobetasol Propionate 0.05%
C: Arm Label: Baricitinib High Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: Baricitinib Low Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-Label Addenda Baricitinib High Dose; Type: EXPERIMENTAL; Interventions: Drug: Baricitinib | Intervention Type: DRUG; Name: Baricitinib; Assigned to Arm(s): Baricitinib High Dose, Baricitinib Low Dose, Open-Label Addenda Baricitinib High Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Baricitinib High Dose, Baricitinib Low Dose, Placebo
D: Arm Label: Dupilumab; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A